10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2020 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 17, 2021) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Revenue | $ 24,539,800 | 22,319,500 | 21,493,300 |
| Costs, expenses, and other: | |||
| Cost of sales | 5,483,300 | 4,721,200 | 4,681,700 |
| Research and development | 6,085,700 | 5,595,000 | 5,051,200 |
| Marketing, selling, and administrative | 6,121,200 | 6,213,800 | 5,975,100 |
| Acquired in-process research and development (Note 3) | 660,400 | 239,600 | 1,983,900 |
| Asset impairment, restructuring, and other special charges (Note 5) | 131,200 | 575,600 | 266,900 |
| Othernet, (income) expense (Note 18) | (1,171,900) | (291,600) | (145,600) |
| Costs, expenses, and other | 17,309,900 | 17,053,600 | 17,813,200 |
| Income before income taxes | 7,229,900 | 5,265,900 | 3,680,100 |
| Income taxes (Note 14) | 1,036,200 | 628,000 | 529,500 |
| Net income from continuing operations | 6,193,700 | 4,637,900 | 3,150,600 |
| Net income from discontinued operations (Note 19) | 0 | 3,680,500 | 81,400 |
| Net income | 6,193,700 | 8,318,400 | 3,232,000 |
| Earnings per share: | |||
| Earnings from continuing operations - basic (in usd per share) | 6.82 | 4.98 | 3.07 |
| Earnings from discontinued operations - basic (in usd per share) | 0.00 | 3.95 | 0.07 |
| Earnings per share - basic (in usd per share) | 6.82 | 8.93 | 3.14 |
| Earnings from continuing operations - diluted (in usd per share) | 6.79 | 4.96 | 3.05 |
| Earnings from discontinued operations - diluted (in usd per share) | 0.00 | 3.93 | 0.08 |
| Earnings per share - diluted (in usd per share) | 6.79 | 8.89 | 3.13 |
| Shares used in calculation of earnings per share: | |||
| Basic (in shares) | 907,634 | 931,059 | 1,027,721 |
| Diluted (in shares) | 912,505 | 935,684 | 1,033,667 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2020 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 17, 2021) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Net income | $ 6,193,700 | 8,318,400 | 3,232,000 |
| Other comprehensive income (loss) from continuing operations: | |||
| Change in foreign currency translation gains (losses) | 122,100 | (89,900) | (429,600) |
| Change in net unrealized gains (losses) on securities | 14,200 | 34,400 | (8,800) |
| Change in defined benefit pension and retiree health benefit plans (Note 15) | (157,100) | (970,000) | 544,000 |
| Change in effective portion of cash flow hedges | (152,900) | 34,300 | |
| Change in effective portion of cash flow hedges | (6,000) | ||
| Other comprehensive income (loss) from continuing operations before income taxes | (173,700) | (991,200) | 99,600 |
| Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations | 200,900 | 151,000 | (30,300) |
| Net other comprehensive income (loss) | 27,200 | (783,400) | 83,600 |
| Comprehensive income | 6,220,900 | 7,535,000 | 3,315,600 |
| Operating Activities | |||
| Continuing Operations | |||
| Net other comprehensive income (loss) | 27,200 | (840,200) | 69,300 |
| Discontinued Operations | |||
| Net other comprehensive income (loss) | 0 | 56,800 | 14,300 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2020 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 17, 2021) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income | $ 6,193,700 | 8,318,400 | 3,232,000 |
| Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: | |||
| Gain related to disposition of Elanco (Note 19) | 0 | (3,680,500) | 0 |
| Gain on sale of antibiotic business in China (Note 3) | 0 | (309,800) | 0 |
| Depreciation and amortization | 1,323,900 | 1,232,600 | 1,609,000 |
| Change in deferred income taxes | (134,500) | 62,400 | 326,800 |
| Stock-based compensation expense | 308,100 | 312,400 | 279,500 |
| Net investment gains | (1,438,500) | (403,100) | (27,000) |
| Acquired in-process research and development (Note 3) | 660,400 | 239,600 | 1,983,900 |
| Other non-cash operating activities, net | 333,900 | 751,800 | 499,000 |
| Other changes in operating assets and liabilities, net of acquisitions and divestitures: | |||
| Receivables(increase) decrease | (1,350,200) | (127,200) | (996,700) |
| Inventories(increase) decrease | (533,400) | (258,700) | 7,800 |
| Other assets(increase) decrease | (457,100) | (602,300) | (980,000) |
| Income taxes payableincrease (decrease) | 322,000 | (221,300) | (125,300) |
| Accounts payable and other liabilitiesincrease (decrease) | 1,271,300 | (477,700) | (284,500) |
| Net Cash Provided by Operating Activities | 6,499,600 | 4,836,600 | 5,524,500 |
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,387,900) | (1,033,900) | (1,210,600) |
| Proceeds from sales and maturities of short-term investments | 129,700 | 136,600 | 2,552,500 |
| Purchases of short-term investments | (11,400) | (42,700) | (112,200) |
| Proceeds from sales of noncurrent investments | 757,100 | 609,800 | 3,509,500 |
| Purchases of noncurrent investments | (358,700) | (247,500) | (837,900) |
| Purchases of in-process research and development | (641,200) | (319,600) | (1,807,600) |
| Cash paid for acquisitions, net of cash acquired (Note 3) | (849,300) | (6,917,700) | 0 |
| Cash distributed to Elanco upon disposition | 0 | (374,000) | 0 |
| Cash received for sale of antibiotic business in China | 0 | 354,800 | 0 |
| Other investing activities, net | 102,800 | (248,700) | (187,700) |
| Net Cash Provided by (Used for) Investing Activities | (2,258,900) | (8,082,900) | 1,906,000 |
| Cash Flows from Financing Activities | |||
| Dividends paid | (2,687,100) | (2,409,800) | (2,311,800) |
| Net change in short-term borrowings | (1,494,200) | 995,400 | (2,197,900) |
| Proceeds from issuance of long-term debt | 2,062,300 | 6,556,400 | 2,477,700 |
| Repayments of long-term debt | (276,500) | (2,866,400) | (1,009,100) |
| Purchases of common stock | (500,000) | (4,400,000) | (4,150,700) |
| Net proceeds from Elanco initial public offering (Note 19) | 0 | 0 | 1,659,700 |
| Other financing activities, net | (241,600) | (200,100) | (372,800) |
| Net Cash Used for Financing Activities | (3,137,100) | (2,324,500) | (5,904,900) |
| Effect of exchange rate changes on cash and cash equivalents | 216,000 | (89,900) | (63,600) |
| Net increase (decrease) in cash and cash equivalents | 1,319,600 | (5,660,700) | 1,462,000 |
| Cash and cash equivalents at beginning of year (includes $677.5 (2019) and $324.4 (2018) of discontinued operations) | 2,337,500 | 7,998,200 | |
| Cash and Cash Equivalents at End of Year (includes $677.5 (2018) of discontinued operations) | 3,657,100 | 2,337,500 | 7,998,200 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ELI LILLY & CO | ||
Ticker: LLY Fiscal Year: 2020 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 17, 2021) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents (Note 7) | $ 3,657,100 | 2,337,500 |
| Short-term investments (Note 7) | 24,200 | 101,000 |
| Accounts receivable, net of allowances of $25.9 (2020) and $22.4 (2019) | 5,875,300 | 4,547,300 |
| Other receivables | 1,053,700 | 994,200 |
| Inventories (Note 6) | 3,980,300 | 3,190,700 |
| Prepaid expenses and other | 2,871,500 | 2,538,900 |
| Total current assets | 17,462,100 | 13,709,600 |
| Investments (Note 7) | 2,966,800 | 1,962,400 |
| Goodwill (Note 8) | 3,766,500 | 3,679,400 |
| Other intangibles, net (Note 8) | 7,450,000 | 6,618,000 |
| Deferred tax assets (Note 14) | 2,830,400 | 2,572,600 |
| Property and equipment, net (Note 9) | 8,681,900 | 7,872,900 |
| Other noncurrent assets | 3,475,400 | 2,871,200 |
| Total assets | 46,633,100 | 39,286,100 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt (Note 11) | 8,700 | 1,499,300 |
| Accounts payable | 1,606,700 | 1,405,300 |
| Employee compensation | 997,200 | 915,500 |
| Sales rebates and discounts | 5,853,000 | 4,933,600 |
| Dividends payable | 770,600 | 671,500 |
| Income taxes payable (Note 14) | 495,100 | 160,600 |
| Other current liabilities | 2,750,300 | 2,189,400 |
| Total current liabilities | 12,481,600 | 11,775,200 |
| Other Liabilities | ||
| Long-term debt (Note 11) | 16,586,600 | 13,817,900 |
| Accrued retirement benefits (Note 15) | 4,094,500 | 3,698,200 |
| Long-term income taxes payable (Note 14) | 3,837,800 | 3,607,200 |
| Other noncurrent liabilities | 1,707,500 | 1,501,000 |
| Deferred tax liabilities (Note 14) | 2,099,900 | 2,187,500 |
| Total other liabilities | 28,326,300 | 24,811,800 |
| Commitments and Contingencies (Note 16) | ||
| Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) | ||
| Common stockno par value Authorized shares: 3,200,000 Issued shares: 957,077 (2020) and 958,056 (2019) | 598,200 | 598,800 |
| Additional paid-in capital | 6,778,500 | 6,685,300 |
| Retained earnings | 7,830,200 | 4,920,400 |
| Employee benefit trust | (3,013,200) | (3,013,200) |
| Accumulated other comprehensive loss (Note 17) | (6,496,400) | (6,523,600) |
| Cost of common stock in treasury | (55,700) | (60,800) |
| Total Eli Lilly and Company shareholders' equity | 5,641,600 | 2,606,900 |
| Noncontrolling interests | 183,600 | 92,200 |
| Total equity | 5,825,200 | 2,699,100 |
| Total liabilities and equity | 46,633,100 | 39,286,100 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |